Standards of Care in the Frontline Treatment of ER+/HER2- mBC

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

Related Videos
Nathalie McDowell Johnson, MD, FACS
William M. Sikov, MD
Lisa A. Carey MD, ScM, FASCO
Susan Domchek, MD, FASCO
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Jean Wright, MD
Steven Cai, MD, FACS
Hyman B. Muss, MD
Expert on breast cancer
Priyanka Sharma, MD
Related Content

Implementation of Early End Points Could Represent New Standard for Breast Cancer Clinical Trials

March 30th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Ribociclib Plus Endocrine Therapy Meets iDFS End Point in HR+ Early Breast Cancer

March 27th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer

March 24th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

Implementation of Early End Points Could Represent New Standard for Breast Cancer Clinical Trials

March 30th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Ribociclib Plus Endocrine Therapy Meets iDFS End Point in HR+ Early Breast Cancer

March 27th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer

March 24th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

Implementation of Early End Points Could Represent New Standard for Breast Cancer Clinical Trials

March 30th 2023

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Ribociclib Plus Endocrine Therapy Meets iDFS End Point in HR+ Early Breast Cancer

March 27th 2023

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Results of NRG-BR002 Trial Point to Need for Additional Research of Local Therapy for Oligometastatic Breast Cancer

March 24th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023